Bahadır KÜLAH, Derya ÇAYIR, MEHMET BOZKURT

TİROİDEKTOMİ SONRASI REZİDÜ DOKU TESPİT EDİLEN DİFERANSİYE TİROİD KARSİNOMLU HASTALARIN BAŞVURU ÖZELLİKLERİ, TEDAVİ VE TAKİP SONUÇLARI

Amaç: Postoperatif radyoaktif iyot (RAI) ablasyonu, diferansiye tiroid karsinomlarında (DTK) tiroidektomi sonrası ta-mamlayıcı tedavi seçeneklerinden birisidir. Tiroidektomi sonrası rezidü dokunun değerlendirilmesi, postoperatif RAIablasyonunun etkinliği açısından önemlidir. Çalışmamızda total tiroidektomi (TT) sonrası rezidü doku tespit edilmişDTK’lı olgularda başvuru özellikleri, tedavi ve takip sonuçlarını retrospektif olarak inceledik.Hastalar ve Metod: Ocak 2014-Temmuz 2018 tarihleri arasında tiroidektomi sonrası patoloji sonucu DTK olarakraporlanan, postoperatif sintigrafide rezidü tiroid dokusu tespit edilmiş 187 (165 kadın, 22 erkek) hasta çalışmayadahil edildi. Yaş, cinsiyet, ultrasonografi bulguları, ince iğne aspirasyon biyopsi (İİAB) sonuçları, yapılan cerrahi giri-şimin tipi, tümör çapı, multifokalite, postoperatif serum tiroglobulin (Tg) düzeyi, tiroid sintigrafisi, RAI ablasyonu velokorejyonel rekürrens gibi parametreler Windows için SPSS 18.0 programı ile Mann Whitney-U, Kruskal Wallis veki-kare testleri kullanılarak değerlendirildi. P değeri < 0,05 ise anlamlı kabul edildi.Bulgular: Tüm hastaların tiroidektomi spesimenlerinin histopatolojik değerlendirme sonucu DTK iken, ameliyat ön-cesi sadece 44’ünde (%24) İİAB sonucu malign ya da malignite şüphesi olarak raporlanmıştı. 45 yaşından büyükhasta grubunda papiller tiroid mikrokarsinomu (PTMK) anlamlı olarak daha sık gözlendi (p

Presentations and Outcomes of Patients with Residual Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma

Aim: Postoperative radioactive iodine (RAI) ablation is one of the options for complementary treatment after thyroidectomy of differentiated thyroid carcinoma (DTC). The evaluation of the residual tissue after thyroidectomy is important for the effectiveness of RAI ablation. In our study, we evaluate the presentation and outcomes of the patients with residual thyroid tissue and aimed to identify the risk factors related with the presence of the residual thyroid tissue. Patients and Methods: 187 (165 female, 22 male) patients, were reported as DTC and postoperative scintigraphy revealed residual thyroid tissue between January 2014 and July 2018, were enrolled in the study. The parameters including age, gender, ultrasonography findings, fine needle aspiration cytology (FNAC) reports, type of the surgery, tumour diameter, multifocality, postoperative serum thyroglobulin (Tg) levels, thyroid scintigraphy, RAI ablation, and locoregional recurrence were compared by Mann Whitney-U, Kruskal Wallis, and qi-square test in SPSS 18.0 for Windows software. P value is accepted as significant if below 0.05. Results: Thyroidectomy specimens of all patients were reported as DTC, Preoperatively only in 44 (24%) patients were reported as malign or suspicion of malignancy according to the results of FNAC. Papillary thyroid microcarcinoma (PTMC) was significantly more common in the group of patients older than 45 (p

PDF

___

Kaliszewski K, Zubkiewicz-Kucharska A, Kiełb P, Maksymow- icz J, Krawczyk A, Krawiec O. Comparison of the prevalence of incidental and non-incidental papillary thyroid microcarcinoma during 2008-2016: a single-center experience. World J Surg Oncol. 2018;16(1):202.
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klop- per JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocri- nol Metab. 2009;94(6):2092-8.
Ertorer ME, Tutuncu NB, Ozyilkan O. Incidental papillary micro- carcinoma of the thyroid. Asian Pac J Cancer Prev. 2007;8(4):631-4.
Kaliszewski K, Wojtczak B, Strutyńska-Karpińska M, Łukieńczuk T, Forkasiewicz Z, Domosławski P. Incidental and non-incidental thyroid microcarcinoma. Oncol Lett. 2016;12(1):734-40.
Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R, Fahey TJ 3rd. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid. 2009 May;19(5):473-7.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
Khammash NF, Halkar RK, Abdel-Dayem HM. The use of technetium-99m pertechnetate in postoperative thyroid carcinoma. A comparative study with iodine-131. Clin Nucl Med. 1988;13(1):17-22.
Ozdemir D, Cuhaci FN, Ozdemir E, Aydin C, Ersoy R, Turkolmez S, et al. The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer. Nucl Med Commun. 2016;37(6):640-5.
Ha S, Oh SW, Kim YK, Koo do H, Jung YH, Yi KH, et al. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer. J Korean Med Sci. 2015;30(7):876-81.
Rosario PW, dos Santos JB, Calsolari MR. Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study. Horm Metab Res. 2013;45(12):911-4.
Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Cross G. Bio- chemical persistence in thyroid cancer: is there anything to worry about? Endocrine. 2014;46(3):532-7.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-22.
Miyauchi A. Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. World J Surg. 2016;40(3):516-22.
Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"- -screening and overdiagnosis. N Engl J Med. 2014;371(19):1765-7.
Lee YS, Lee BJ, Hong HJ, Lee KD. Current trends of practical issues concerning micropapillary thyroid carcinoma: The Korean Society of Thyroid-Head and Neck Surgery. Medicine (Baltimore). 2017;96(45):e8596.
Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol. 2018 Mar;44(3):307-315.
Brito JP, Ito Y, Miyauchi A, Tuttle RM. A Clinical Framework to Fa- cilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarci- noma. Thyroid. 2016;26(1):144-9.
Sugitani I. Active surveillance for very low-risk papillary thyroid carcinoma: experience and perspectives from Japan. Annals of Thyroid. 2018;3:26-26. 10.21037/aot.2018.10.04.
Zhang X, Zhang L, Xue S, Wang P, Chen G. Predictive factors of lateral lymph node metastasis in solitary papillary thyroid microcar- cinoma without gross extrathyroidal extension. Asian J Surg. 2018 Aug 3. pii: S1015-9584(18)30365-8.
Liu G, Li N, Li X, Chen S, Du B, Li Y. Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging. Biomed Res Int. 2016;2016:4763824.
Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, et al. Natural history, diagnosis, treatment and outcome of papil- lary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun. 2004;25(6):547-52.
Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91(6):2171-8
Vlassopoulou V, Vryonidou A, Paschou SA, Ioannidis D, Koletti A, Klonaris N, et al. No considerable changes in papillary thyroid microcarcinoma characteristics over a 30-year time period. BMC Res Notes. 2016;9(1):252.
Lombardi CP, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34(6):1214-21.
Mehanna H, Al-Maqbili T, Carter B, Martin E, Campain N, Watkinson J, et al. Differences in the recurrence and mortality out- comes rates of incidental and nonincidental papillary thyroid micro- carcinoma: a systematic review and meta-analysis of 21 329 person- years of follow-up. J Clin Endocrinol Metab. 2014;99(8):2834-43.
Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol. 2014;21(4):1379-83.
Verkooijen RB, Stokkel MP, Smit JW, Pauwels EK. Radioio- dine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging. 2004;31(4):499-506.